Form 4: CareDx Director George Bickerstaff Receives RSU Grant

Director George Bickerstaff acquired 9,795 restricted stock units in CareDx, Inc. as part of a standard equity compensation grant.

Summary

• Director George Bickerstaff was granted 9,795 restricted stock units (RSUs) on June 12, 2026.
• The grant was issued at a price of $0 per share, representing equity compensation.
• Following this transaction, the director's total beneficial ownership in CareDx, Inc. increased to 154,061 shares of common stock.
• The transaction was executed under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The director's increased equity stake aligns his interests with those of the shareholders.

Negatives

• None identified.

Risks

• Vesting of the RSUs is contingent upon the director's continuous service to the company.

Future Outlook

The RSUs vest 100% on the earlier of the one-year anniversary of the grant or the day immediately before the first Annual Meeting occurring after the grant date, subject to continuous service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to incentivize long-term board commitment and alignment with shareholder value in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-cap healthcare companies.
• The use of a Rule 10b5-1 plan for equity transactions is a best-practice standard for corporate insiders to avoid potential conflicts of interest.

Stakeholder Impact

• Shareholders benefit from the continued alignment of board members with company performance.

Next Steps

• Vesting of the 9,795 RSUs on the earlier of the one-year anniversary or the day before the next Annual Meeting.

Key Dates

Keywords

CareDx, CDNA, Form 4, Insider Trading, Equity Compensation, Director Ownership